Articles

ADAPT-DES study TCT, 2012, Plavix, stent

November 2, 2012 — Patients who receive a drug-eluting stent (DES) and demonstrate low levels of platelet inhibition are more likely to have blood clots form on the stent and suffer a possible...

September 7, 2012 — St. Jude Medical Inc. announced results of the FAME II trial demonstrating that patients with...

Verifynow platelet testing clopidogrel nonresponders

Patients with 2C19 that is less active due to loss of gene copies are poor metabolizers of clopidogrel, opening patients to the possibility of a higher rate of mayocardial infacrtion (...

The standard-of-care for dual antiplatelet therapy (DAPT) for more than a decade has been clopidogrel (Plavix) plus aspirin. This standard is now being challenged by new agents —...

August 23, 2012 — Decision Resources, a research and advisory firm for pharmaceutical and healthcare issues, finds that the 12-month post-hospital acute coronary syndrome market will initially...

July 20, 2012 — Ticagrelor, a blood-thinning drug approved by the U.S. Food and Drug Administration (FDA) in 2011, should be considered along with older blood thinners clopidogrel and prasugrel...

Over the past decade there have been several advancements in prothrombin time (PT)/international normalized ration (INR) point-of-care testing (POCT) devices. This is usually performed at an...

June 22, 2012 — The the U.S. Food and Drug Administration’s (FDA) Cardiovascular and Renal Drugs Advisory Committee voted in May against recommending approval of expanding the indication for...

The U.S. Food and Drug Administration (FDA) today approved generic versions of the blood-thinning drug Plavix (clopidogrel), which is expected to have a major impact on the cost to treat patients...